Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Testing the Cre-mediated genetic switch for the generation of conditional knock-in mice.

Capulli M, Costantini R, Sonntag S, Maurizi A, Paganini C, Monti L, Forlino A, Shmerling D, Teti A, Rossi A.

PLoS One. 2019 Mar 13;14(3):e0213660. doi: 10.1371/journal.pone.0213660. eCollection 2019.

2.

Osteoblasts Regulate Angiogenesis in Response to Mechanical Unloading.

Veeriah V, Paone R, Chatterjee S, Teti A, Capulli M.

Calcif Tissue Int. 2019 Mar;104(3):344-354. doi: 10.1007/s00223-018-0496-z. Epub 2018 Nov 21.

PMID:
30465120
3.

Regulation of breast cancer induced bone disease by cancer-specific IKKβ.

Marino S, Bishop RT, Capulli M, Sophocleous A, Logan JG, Mollat P, Mognetti B, Ventura L, Sims AH, Rucci N, Ralston SH, Idris AI.

Oncotarget. 2018 Mar 23;9(22):16134-16148. doi: 10.18632/oncotarget.24743. eCollection 2018 Mar 23.

4.

RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development.

Maurizi A, Capulli M, Patel R, Curle A, Rucci N, Teti A.

Bone. 2018 May;110:343-354. doi: 10.1016/j.bone.2018.02.031. Epub 2018 Mar 6.

PMID:
29501587
5.

A Complex Role for Lipocalin 2 in Bone Metabolism: Global Ablation in Mice Induces Osteopenia Caused by an Altered Energy Metabolism.

Capulli M, Ponzetti M, Maurizi A, Gemini-Piperni S, Berger T, Mak TW, Teti A, Rucci N.

J Bone Miner Res. 2018 Jun;33(6):1141-1153. doi: 10.1002/jbmr.3406. Epub 2018 Mar 24.

PMID:
29444358
6.

TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.

Peramuhendige P, Marino S, Bishop RT, de Ridder D, Khogeer A, Baldini I, Capulli M, Rucci N, Idris AI.

Sci Rep. 2018 Jan 8;8(1):39. doi: 10.1038/s41598-017-18327-5.

7.

Non-conventional role of haemoglobin beta in breast malignancy.

Ponzetti M, Capulli M, Angelucci A, Ventura L, Monache SD, Mercurio C, Calgani A, Sanità P, Teti A, Rucci N.

Br J Cancer. 2017 Sep 26;117(7):994-1006. doi: 10.1038/bjc.2017.247. Epub 2017 Aug 3.

8.

Interleukin-1β, lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk.

Veeriah V, Zanniti A, Paone R, Chatterjee S, Rucci N, Teti A, Capulli M.

Sci Rep. 2016 Jul 19;6:29880. doi: 10.1038/srep29880.

9.

Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.

Capulli M, Maurizi A, Ventura L, Rucci N, Teti A.

Mol Ther Nucleic Acids. 2015 Sep 1;4:e248. doi: 10.1038/mtna.2015.21.

10.

Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation.

Cappariello A, Paone R, Maurizi A, Capulli M, Rucci N, Muraca M, Teti A.

Biomaterials. 2015 Apr;46:58-69. doi: 10.1016/j.biomaterials.2014.12.033. Epub 2015 Jan 17.

11.

The α2β1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: a preclinical study.

Rucci N, Capulli M, Olstad OK, Önnerfjord P, Tillgren V, Gautvik KM, Heinegård D, Teti A.

Cancer Lett. 2015 Mar 1;358(1):67-75. doi: 10.1016/j.canlet.2014.12.032. Epub 2014 Dec 18.

PMID:
25529009
12.

Generation and culture of osteoclasts.

Marino S, Logan JG, Mellis D, Capulli M.

Bonekey Rep. 2014 Sep 10;3:570. doi: 10.1038/bonekey.2014.65. eCollection 2014.

13.

Lipocalin 2: a new mechanoresponding gene regulating bone homeostasis.

Rucci N, Capulli M, Piperni SG, Cappariello A, Lau P, Frings-Meuthen P, Heer M, Teti A.

J Bone Miner Res. 2015 Feb;30(2):357-68. doi: 10.1002/jbmr.2341.

14.

Osteoblast and osteocyte: games without frontiers.

Capulli M, Paone R, Rucci N.

Arch Biochem Biophys. 2014 Nov 1;561:3-12. doi: 10.1016/j.abb.2014.05.003. Epub 2014 May 14. Review.

PMID:
24832390
15.

The C-terminal domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss.

Capulli M, Olstad OK, Onnerfjord P, Tillgren V, Muraca M, Gautvik KM, Heinegård D, Rucci N, Teti A.

J Bone Miner Res. 2014 Aug;29(8):1833-46. doi: 10.1002/jbmr.2206.

16.

Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression.

Sanità P, Capulli M, Teti A, Galatioto GP, Vicentini C, Chiarugi P, Bologna M, Angelucci A.

BMC Cancer. 2014 Mar 5;14:154. doi: 10.1186/1471-2407-14-154.

17.

Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models.

Alam I, Gray AK, Chu K, Ichikawa S, Mohammad KS, Capannolo M, Capulli M, Maurizi A, Muraca M, Teti A, Econs MJ, Del Fattore A.

Bone. 2014 Feb;59:66-75. doi: 10.1016/j.bone.2013.10.021. Epub 2013 Nov 1.

18.

An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6.

Del Fattore A, Cappariello A, Capulli M, Rucci N, Muraca M, De Benedetti F, Teti A.

Osteoporos Int. 2014 Feb;25(2):681-92. doi: 10.1007/s00198-013-2479-2. Epub 2013 Aug 14.

PMID:
23943168
19.

Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.

Rucci N, Capulli M, Ventura L, Angelucci A, Peruzzi B, Tillgren V, Muraca M, Heinegård D, Teti A.

J Bone Miner Res. 2013 Sep;28(9):1912-24. doi: 10.1002/jbmr.1951.

20.

Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.

Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, Ventura L, Bologna M, Flamini S, Moreschini O, Lidereau R, Ricevuto E, Muraca M, Teti A, Rucci N.

J Bone Miner Res. 2012 Nov;27(11):2387-98. doi: 10.1002/jbmr.1686.

21.

NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains.

Cardone RA, Greco MR, Capulli M, Weinman EJ, Busco G, Bellizzi A, Casavola V, Antelmi E, Ambruosi B, Dell'Aquila ME, Paradiso A, Teti A, Rucci N, Reshkin SJ.

Mol Biol Cell. 2012 Jun;23(11):2028-40. doi: 10.1091/mbc.E11-11-0911. Epub 2012 Apr 11.

22.

Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.

Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, Pierroz D, Morandi L, De Simone M, Rucci N, Bertini E, Bianchi ML, De Benedetti F, Teti A.

J Bone Miner Res. 2011 Aug;26(8):1891-903. doi: 10.1002/jbmr.410.

23.

Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases.

Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A, Baldini N.

Curr Cancer Drug Targets. 2010 Nov;10(7):649-59.

PMID:
20578992
24.

The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis.

Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante V, Zazzeroni F, Alesse E, Heinegård D, Teti A.

J Cell Biol. 2009 Nov 30;187(5):669-83. doi: 10.1083/jcb.200906014.

25.
26.

Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice.

Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, Cavat F, Rizzoli R, Teti A, Bouxsein ML, Ferrari SL.

J Bone Miner Res. 2009 May;24(5):775-84. doi: 10.1359/jbmr.081237.

27.

[Concentration test for determination of low-level HBsAg in donors with anti-HBc].

Maschio C, Varrassi S, Barnabei R, Rughetti A, Fonzi D, Capulli M, Genise S.

Riv Emoter Immunoematol. 1985;32(1):69-73. Italian. No abstract available.

PMID:
4081534

Supplemental Content

Loading ...
Support Center